<< Revenir à la page d'accueil
13th november 2012
Maison de la Chimie, Paris
Anticancer immunity: a « must » to cure cancer
Laurence ZITVOGEL
Inserm Université Paris Sud - Institut Gustave-Roussy, Villejuif
⤢
Anticancer immunity: a « must » to cure cancer Tumor Immunology and Immunotherapy of Cancer
Direct and Indirect « off target » effects of the tumoricidal activity of compounds
Conceptual Breakthrough: Immunogenic cell death
Immunogenic cell death (ICD): the rules
Immunogenic cell death (ICD): the rules for compounds
How to screen drugs for ICD ? Robotized fluorescence videomicroscopy
An example of a high content screening of a public drug library
Immunogenic cell death (ICD): the rules for tumors
Immunogenic cell death (ICD): the rules for hosts
Immunogenic cell death (ICD): TLR4/HMGB1 interaction mandatory for ICD
Not lost in translation....
TLR4 loss of function polymorphisms associated with chemoresistance in breast cancers
HMGB1 negative breast cancers associated with failure to benefit from adjuvant anthracyclines
Next steps: Prospective validation and clinical trial with compensatory therapy (TLR4/MyD88 agonist) Neoadjuvant Breast Cancers
Conclusion and Perspectives: Immunogenic cell death
|«
«
▶||
»
»|
0:00:00